Intraperitoneal XXXX in the treatment of @entity298 following second-look surgery.

@entity1 @entity43 @entity1204 @entity137 @entity882 @entity5 @entity1138 @entity900 @entity490 @entity298 @entity1487
Persistent or recurrent @entity298 ( @entity298 ) documented at second-look surgery has proved relatively refractory to second-line therapy. The majority of these @entity5 do not respond to @entity900 based chemotherapy. Because of the relatively high response rate we observed with systemically administered @entity1138 plus @entity1487 , we initiated a trial of intraperitoneal (IP) @entity1138 (10 mg/m2 in 2 L dialysate fluid every 4 weeks) in 14 @entity1 with refractory @entity298 secondary to gynecologic @entity5 . All but one @entity1 had @entity298 secondary to @entity43 documented at second-look cytoreductive surgery following intense @entity900 based drug therapy. One @entity1 had @entity1204 and had been treated previously with radiation. In all, 49 courses of intraperitoneal @entity1138 were administered to 14 @entity1 . Systemic @entity137 was minimal, except for mild @entity882 that occurred in four @entity1 . However, @entity490 due to @entity298 was cumulative and dose limiting after three to five courses of therapy. Of the seven @entity1 with measurable disease (positive serum CA-125 or intraperitoneal cytology), six had normalization of at least one of these two parameters. Eight of the 14 @entity1 remain alive without clinical evidence of disease with a median follow-up duration of 10 months. We conclude that IP @entity1138 is a well-tolerated and potentially effective treatment modality in @entity1 with limited @entity298 following second-look surgical debulking for gynecologic @entity5 .
